Skip to main content

Table 1 Summary of the patient populations by treatment arm in the five clinical trials

From: Multiple treatment comparisons in a series of anti-malarial trials with an ordinal primary outcome and repeated treatment evaluations

       Day14 Day21 Day28
Study Year Treat m 1 m 2 m 3 ACPR LPF LCF ACPR LPF LCF NA ACPR LPF LCF NA
#                 
  2005 AQ 64 3 61 58 2 1 54 0 2 5 50 2 2 7
  Feb-May ASAQ 60 3 57 56 0 1 49 0 4 4 43 3 3 8
1   ASSP 61 3 58 58 0 0 55 1 1 1 50 3 2 3
  Subtotal   185 9 176 172 2 2 158 1 7 10 143 8 7 18
  2006 1 AQSP 67 3 64 64 0 0 61 1 1 1 55 1 4 4
  Apr-Jul ASMQ 69 8 61 61 0 0 61 0 0 0 60 1 0 0
2 Subtotal   136 11 125 125 0 0 122 1 1 1 115 2 4 4
  2006 2 ASAQ 62 4 58 58 0 0 52 4 1 1 52 0 0 6
  Sep-Nov AMLM 61 1 60 60 0 0 58 2 0 0 58 0 0 2
3 Subtotal   123 5 118 118 0 0 110 6 1 1 110 0 0 8
  2006 3 ASCD 86 14 72 71 1 0 57 6 8 1 53 2 1 16
4 Dec-Feb ASSP 82 1 81 81 0 0 79 0 2 0 74 2 2 3
  Subtotal   168 15 153 152 1 0 136 6 10 1 110 0 0 19
  2007 ASAQ 92 4 88 87 1 0 78 6 3 1 73 5 0 10
5 Apr-Jul DHPP 91 5 86 86 0 0 86 0 0 0 84 2 0 0
  Subtotal   183 9 164 173 1 0 164 6 3 1 157 7 0 10
  Subtotal ASAQ 214 11 203 201 1 1 179 10 8 6 168 8 3 24
   Others 581 38 543 539 3 1 513 10 14 8 484 13 11 35
  Total   795 49 746 740 4 2 690 20 22 14 652 21 14 59
  1. m1: number of included patients, m2: number of drop-out and lost to follow-up before Day 14, m3: number of evaluated patients on Day 14. ACPR adequate clinical and parasitological response, LPF late parasitological failure, LCF late clinical failure), NA: not available outcome. AQ, amodiaquine; SP, sulphadoxine-pyrimethamine; AS, artesunate; AM, artemether; DHPP, dihydroartemisinin-piperaquine; LM, lumefantrine; CD, chlorproguanil-dapsone.